About half of all mental health problems in adulthood have their onset during or before adolescence. Improving resilience to mental illness among young people is very important, as poor mental health in adolescence is linked to unemployment, crime, increased rates of smoking, drug use, obesity and future mental ill health. Support and early interventions designed to promote well-being are key to building such resilience.
Feeling low from time to time can be normal for adolescents. However, regular and prolonged periods of low mood can progress to depression and negatively impact long-term health, well-being and development.
Being in good emotional and physical health enables young people to deal with the challenges of adolescence and eases their transition into adulthood. Positive mental well-being in childhood is associated with increased social competence and good coping strategies that lead to more positive outcomes in adulthood. Addressing low feelings among young people and teaching them coping mechanisms that promote resilience is vital to protecting and promoting their mental health.
For more information about adolescents and mental health on the euro.who.int website
The European Commission has produced two new guides about blood management:
- Building national programmes of patient blood management (PBM) in the EU – a guide for health authorities
- Supporting patient blood management (PBM) in the EU – a practical implementation guide for hospitals
To download these guides on patient blood management from the ec.europa.eu website
Across the world, more than 3,000 adolescents die every day from largely preventable causes according to a report from the World Health Organisation.
Road traffic injuries, lower respiratory infections, and suicide are the biggest causes of death among adolescents and most of these could be prevented with good health services, education and social support. However, in many cases, adolescents who suffer from mental health disorders, substance use, or poor nutrition cannot obtain critical prevention and care services – either because the services do not exist, or because they do not know about them.
In addition, many behaviours that impact health later in life, such as physical inactivity, poor diet, and risky sexual health behaviours, begin in adolescence.
To read more about preventable adolescent deaths on the who.int website
There have been no HIV or Hepatitis infections from blood transfusions in the last 10 years in Italy.
More than three million transfusions of blood components were made in 2015, with 1709 positive cases of HIV or Hepatitis detected in 1691 donors, who were therefore disqualified from giving blood. This screening system ensures the safety of receiving blood and its components.
To read more (in Italian) about safe blood transfusions on the salute.gov.it website
In 1972, Finland had the highest rate of coronary heart disease (CHD) mortality in the world, and the region of North Karelia in eastern Finland had the highest rate in the country. To address this issue, the region initiated what is known as the North Karelia Project, a far-reaching, community-based intervention that aims to reduce CHD mortality by encouraging healthier habits and cutting down on risk factors such as high cholesterol intake and smoking.
The project is still active today and has produced remarkable results. During the 40-year period from 1972 to 2012, CHD mortality in North Karelia decreased by 82% among working-age men and 84% among women.
To read more about Finland’s method of reducing noncommunicable diseases from the euro.who.int website
Some 50 million Europeans live with multi-morbidity and their numbers are likely to grow. As they have complex health problems and need ongoing care, policymakers are alarmed by the challenge this poses to their health systems and social services.
The ICARE4EU project has looked at new approaches to integrated care and its findings are shared in five policy briefs:
- How to improve care for people with multi-morbidity?
- How to strengthen patient-centredness in caring for people with multi-morbidity
- How to strengthen financing mechanisms to promote care for people with multi-morbidity
- How can eHealth improve care for people with multi-morbidity
- How to support integration to promote care for people with multi-morbidity
To read more about the project and download the five policy briefs on caring for people with multi-morbidity from the euro.who.int website
Around 1.25 million people die every year on the world’s roads. Studies indicate that:
- almost half of all drivers exceed the speed limit
- drivers who are male, young and under the influence of alcohol are more likely to be involved in speed-related crashes
- road traffic accidents (RTAs) are the number one cause of death among young people aged 15–29 years
- RTAs are estimated to cost countries from 3–5% of GDP and push many families into poverty.
‘Managing speed’, a new report from WHO, suggests that excessive or inappropriate speed contributes to 1 in 3 road traffic fatalities worldwide. Measures to address speed prevent road traffic deaths and injuries, make populations healthier, and cities more sustainable.
To read more about speed management to save lives from the who.int website
Since 1992 when the Maastricht Treaty specifically stated that ‘The community shall contribute towards ensuring a high level of human health protection’ the EU has been protecting our health.
It has helped national governments to make healthcare more accessible and efficient, provided scientific advice and data, financed local and cross-border health projects and promoted investments in innovation, research and training.
Current challenges include:
- Guaranteeing accessible, efficient and resilient healthcare
- Investing more in innovation, research and eHealth
- Tackling antimicrobial resistance
- Promoting innovative health products and technologies
- Preparing for new global health threats
To download the infographic on 25 years of protecting our health from the ec.europa.eu website
Since 2001, EU rules have required the medicines we buy in the EU to contain a package leaflet which should provide us – the user, with clear information on the medicines we are taking – including the name of the product and the manufacturer, therapeutic indications, dosage, shelf life and adverse reactions.
The Commission has recently put forward recommendations on how they could be improved to better meet the needs of patients and healthcare professionals.
To read the recommendations on improved medicine packaging on the ec.europa.eu website
Pharmaceuticals in the environment represent a global pollution problem – over 631 different pharmaceutical agents (or their metabolites) have been detected in at least 71 countries covering all continents. Pharmaceutical residues have been detected in surface water, sewage effluents, groundwater, drinking water, manure, soil, and other environmental matrices. Antibiotics in the environment can promote the development of antibiotic-resistant pathogens – a major global health threat. Also, little is known about the effects on humans from continuous, long-term exposure to low concentrations of pharmaceuticals. Pharmaceutical substances are often engineered so
that they remain unchanged during their passage through the human body; unfortunately this stability means they also persist outside the human body and, as a consequence, can build up in the environment. Several studies have confirmed that medicines pose environmental risks, and that concentrations found in the environment can have detrimental effects on aquatic systems and wildlife.
The Dutch organisation – health care without harm Europe – has produced a report outlining what steps are being taken in Europe to reduce anti-microbial resistance (AMR) and offers opportunities for countries to work together on this shared problem.